Business · 11/07/2018Updated: 10/17/2026 · 1 min read
FDA Requests Public Comment on Proposed Collection of Postmarketing Adverse Drug Experience Reporting and Recordkeeping Information
Summary
The Food and Drug Administration (FDA) is seeking public input on its proposed collection of information related to postmarketing adverse drug experience reporting and recordkeeping, as required by the Paperwork Reduction Act of 1995
Original source language: Federal Register — Food and Drug AdministrationOpen original release →